News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
European operations' revenue grew 58.4% to Rs 599.7 crore
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Subscribe To Our Newsletter & Stay Updated
